|Articles|May 1, 2011

Applied Clinical Trials-05-01-2011
Volume 20
Issue 5

Applied Clinical Trials Digital Edition - May 2011

eCLINICAL : Paperless IRB - Streamlined Efficiency Translating Data into Meaningful Metrics STATISTICS : Review of Categorical Data Analysis LABS : Industry Perspective of Good Clinical Laboratory Practice Also in this issue : Pharmaceutical R&D Funding, Europe 2020 Strategy, Protocol Amendments, Predicting Adverse Events

External Link - article-821539.pdf

Articles in this issue

over 15 years ago

Article

Applied Clinical Trials Digital Edition - May 2011, Supplement

over 15 years ago

Article

GCLP: an Industry Perspective

over 15 years ago

Article

Innovation is in for EU's Healthcare System

over 15 years ago

Article

Study Completion Times

over 15 years ago

Article

Business and News Update May 2011

over 15 years ago

Article

Innovation in Ethical Review

over 15 years ago

Article

Patients are not Schrödinger's Cats

over 15 years ago

Article

Protocol Amendments: a Costly Solution

over 15 years ago

Article

ACT Supplement Cover Image

over 15 years ago

Article

Translating Clinical Data

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

October 27th, 2026

ACT Brief: Community Trial Cost Barriers, Measuring What Matters, and Prostate Cancer Approval

In today’s ACT Brief, we examine how cost barriers and site infrastructure limit participation in community trials, why endpoints should reflect what patients actually experience, and how the FDA expanded a prostate cancer combination to an earlier treatment setting.

October 26th, 2026

How Much of the Community Participation Gap Is About Infrastructure, Not Willingness?

In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patient cost barriers and site infrastructure challenges must be solved together to close the participation gap in community and rural clinical trials.

© FlowStudio - © FlowStudio - stock.adobe.com

October 26th, 2026

Measuring What Matters: Realigning Clinical Endpoints with Patient Reality

Patients don’t experience primary endpoints, so trials that stop at biomarkers and rigid rating scales risk declaring success while leaving daily burden untouched, and digital tools only deliver meaningful evidence when they are co-designed with patients and deployed with restraint.

Exploratory HERO data on ARD-101 in Prader-Willi syndrome arrive a day after FDA lifted the clinical hold, and Aardvark is planning a lower-dose Phase 3. Credit: Stock.Adobe.com/photon_photo

October 23rd, 2026

Aardvark Shares Data From Stopped Prader-Willi Trial as FDA Lifts Hold

Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.

Real-time analytics are not the same as decision readiness. Faster trials depend on data teams can trust when the decision needs to be made. Credit: Stock.Adobe.com/CC/peopleimages.com.

October 23rd, 2026

Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem

Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.

October 23rd, 2026

ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act

In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.

October 22nd, 2026

Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease

The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.

© photon_photo - © photon_photo - stock.adobe.com

October 22nd, 2026

Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology

Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.

Applied Clinical Trials Digital Edition - May 2011

Articles in this issue

Related to this article

Trending on Applied Clinical Trials Online

Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem

Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect

ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act

Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease